全球大麻藥品市場規模、佔有率、成長分析，依品牌（Epidiolex、Sativex）- 2024-2031 年產業預測

Global Cannabis Pharmaceuticals Market Size, Share, Growth Analysis, By Brand(Epidiolex, Sativex) - Industry Forecast 2024-2031

出版日期: 2024年02月27日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2022年全球大麻藥品市場規模為15億美元，預計將從2023年的24.3億美元成長到2031年的1,152.7億美元，在預測期間（2024-2031年）複合CAGR為62%。

大麻在各個醫療領域的廣泛使用是市場擴張的重要驅動力。以大麻為基礎的產品因其在治療一系列疾病方面的功效而日益得到認可，包括關節炎、癌症、帕金森氏症和阿茲海默症等慢性疾病，以及憂鬱症、癲癇和焦慮等神經系統疾病。這些化合物在減輕患者疼痛方面發揮著至關重要的作用，促使疼痛管理中對大麻藥物的需求不斷成長。美國、英國、加拿大等許多國家將大麻用於治療目的合法化，反映了全球對其治療特性的接受轉變，推動了市場成長。美國《MORE 法案》等立法舉措進一步表明政府對大麻合法化的支持，在世界各地引發了類似的運動。隨著政府和消費者擴大接受大麻，醫療保健專業人員正在將大麻療法納入他們的處方中，進一步推動市場擴張。全球接受度和醫療整合的不斷發展趨勢使大麻市場在可預見的未來持續成長。

市場概況
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 歐洲其他地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 拉丁美洲其他地區
中東和非洲 (MEA)
- 海灣合作理事會國家
- 南非
- MEA 的其餘部分

競爭格局

前 5 名企業比較
2021 年關鍵參與者的市場定位
主要市場參與者所採取的策略
最佳制勝策略
近期市集活動
主要公司市佔率（%），2021年

主要公司簡介

Pharmaceutical Group (United Kingdom)
MedReleaf Australia (Australia)
Aurora Cannabis (Canada)
GW Pharmaceuticals (United Kingdom)
Clever Leaves (Colombia)
Cannabis Europa (United Kingdom)
Tilray (Canada)
Aphria Inc. (Canada)
Panaxia Pharmaceuticals (Israel)
Aphria Inc. (Canada)
Cresco Labs (USA)
Canopy Growth Corporation (Canada)
Cronos Group Inc. (Canada)
Green Thumb Industries Inc. (USA)
Charlotte's Web Holdings, Inc. (USA)
Harvest Health & Recreation Inc. (USA)
TerrAscend Corp. (Canada)
Trulieve Cannabis Corp. (USA)
Acreage Holdings, Inc. (USA)
Curaleaf Holdings, Inc. (USA)

簡介目錄

Product Code: SQMIG35I2243

Global Cannabis Pharmaceuticals Market size was valued at USD 1.5 billion in 2022 and is poised to grow from USD 2.43 billion in 2023 to USD 115.27 billion by 2031, growing at a CAGR of 62% in the forecast period (2024-2031).

The extensive use of cannabis across various medical domains serves as a significant driver for market expansion. Cannabis-based products are increasingly recognized for their efficacy in managing a spectrum of illnesses, including chronic conditions like arthritis, cancer, Parkinson's, and Alzheimer's disease, as well as neurological disorders such as depression, epilepsy, and anxiety. These compounds play a crucial role in alleviating patient pain, contributing to the growing demand for cannabis-based medications in pain management. The legalization of cannabis for therapeutic purposes in numerous countries, including the US, UK, Canada, and others, reflects a global shift towards acceptance of its therapeutic properties, propelling market growth. Legislative initiatives such as the MORE Act in the US further signify governmental support for cannabis legalization, igniting similar movements worldwide. As governments and consumers increasingly embrace cannabis, healthcare professionals are integrating cannabis therapies into their prescriptions, further fueling market expansion. This evolving trend towards global acceptance and medical integration positions the cannabis market for sustained growth in the foreseeable future.

Top-down and bottom-up approaches were used to estimate and validate the size of the Cannabis Pharmaceuticals Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Cannabis Pharmaceuticals Market Segmental Analysis

The global cannabis pharmaceuticals market is segmented into epidiolex and sativex on the basis of brand. If the market is divided based on region, we end up with the following segments: North America, Europe, Latin America, Asia- Pacific, Middle East and Africa.

Drivers of the Cannabis Pharmaceuticals Market

A significant catalyst for growth in the cannabis pharmaceutical market is the increasing trend of legalizing medical cannabis in various regions, bolstering the market's potential as more areas embrace its medicinal use. Moreover, the rising acceptance of medical cannabis among patients seeking treatment for conditions like epilepsy, cancer, and chronic pain reflects a positive shift in perceptions, driving continued market expansion. Additionally, the prevalence of chronic diseases treatable with cannabis-based pharmaceuticals, such as multiple sclerosis, depression, and anxiety disorders, contributes to market growth.

Restraints in the Cannabis Pharmaceuticals Market

Challenges persist, including regulatory variations across regions and the need for more robust clinical evidence to establish efficacy and safety. Furthermore, lingering misconceptions and social stigma surrounding cannabis use may deter some healthcare providers and patients from considering cannabis-based treatments, potentially impeding adoption rates.

Market Trends of the Cannabis Pharmaceuticals Market

key market trends such as the diversification of product formats, pharmaceutical partnerships, and advancements in extraction technologies are poised to drive further innovation and growth in the cannabis pharmaceutical sector.

Executive Summary

Market Overview
Wheel of Fortune

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Parent Market Analysis

Market Overview
Market Size
Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges

Key Market Insights

Technology Analysis
Pricing Analysis
Supply Chain Analysis
Value Chain Analysis
Ecosystem of the Market
IP Analysis
Trade Analysis
Startup Analysis
Raw Material Analysis
Innovation Matrix
Pipeline Product Analysis
Macroeconomic Indicators
Top Investment Analysis
Key Success Factor
Degree of Competition

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Regulatory Landscape
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact

Global Cannabis Pharmaceuticals Market by Brand

Market Overview
Epidiolex
Sativex

Global Cannabis Pharmaceuticals Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2021
Strategies Adopted by Key Market Players
Top Winning Strategies
- By Development
- By Company
- By Year
Recent Activities in the Market
Key Companies Market Share (%), 2021

Key Company Profiles

Pharmaceutical Group (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
MedReleaf Australia (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aurora Cannabis (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GW Pharmaceuticals (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Clever Leaves (Colombia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cannabis Europa (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Tilray (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aphria Inc. (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Panaxia Pharmaceuticals (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aphria Inc. (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cresco Labs (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Canopy Growth Corporation (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cronos Group Inc. (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Green Thumb Industries Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Charlotte's Web Holdings, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Harvest Health & Recreation Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
TerrAscend Corp. (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Trulieve Cannabis Corp. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Acreage Holdings, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Curaleaf Holdings, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments